Last 7 days
-7.5%
Last 30 days
-34.4%
Last 90 days
-21.3%
Trailing 12 Months
-68.3%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABBV | 275.0B | 58.1B | 0.21% | 1.63% | 23.24 | 4.74 | 3.30% | 2.55% |
REGN | 80.1B | 12.2B | -0.48% | 14.17% | 18.47 | 6.58 | -24.26% | -46.28% |
VRTX | 77.3B | 8.9B | -1.64% | 19.14% | 23.26 | 8.65 | 17.91% | 41.84% |
INCY | 16.5B | 3.4B | -9.50% | -1.15% | 48.37 | 4.85 | 13.67% | -64.09% |
MID-CAP | ||||||||
NTRA | 6.5B | 820.2M | 33.58% | 88.13% | -11.84 | 7.91 | 31.13% | -16.13% |
ARWR | 2.6B | 278.3M | -26.82% | -37.82% | -16.79 | 9.32 | 92.72% | 15.56% |
SMALL-CAP | ||||||||
VCYT | 1.7B | 296.5M | -8.83% | -2.63% | -45.88 | 5.66 | 35.09% | 51.62% |
CSTL | 594.5M | 137.0M | -12.82% | -37.88% | -8.86 | 4.34 | 45.65% | -114.55% |
CDNA | 517.1M | 321.8M | -34.40% | -68.30% | -6.75 | 1.61 | 8.57% | -149.86% |
NVTA | 341.3M | 516.3M | -32.04% | -78.85% | -0.11 | 0.66 | 12.13% | -719.59% |
ORGO | 276.2M | 450.9M | -22.02% | -71.01% | 17.79 | 0.61 | -3.52% | -83.51% |
CELC | 156.8M | - | -8.44% | 22.89% | -4.41 | - | - | -39.92% |
OPGN | 3.3M | 3.3M | 9.17% | 59.66% | -0.1 | 1.01 | -21.77% | 4.40% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 1.0% | 321,793,000 | 318,629,000 | 314,859,000 | 308,413,000 | 296,397,000 |
Operating Expenses | 1.8% | 399,024,000 | 392,139,000 | 379,757,000 | 356,334,000 | 326,123,000 |
S&GA Expenses | 3.1% | 96,027,000 | 93,183,000 | 92,292,000 | 84,941,000 | 77,245,000 |
R&D Expenses | 1.7% | 90,388,000 | 88,864,000 | 85,997,000 | 82,401,000 | 76,525,000 |
EBITDA | -6.9% | -64,631,000 | -60,459,000 | -41,331,000 | -23,290,000 | - |
EBITDA Margin | -4.6% | -0.20 | -0.19 | -0.13 | -0.08 | - |
Earnings Before Taxes | -1.5% | -76,234,000 | -75,130,000 | -70,517,000 | -50,798,000 | -32,088,000 |
EBT Margin | -0.5% | -0.24 | -0.24 | -0.22 | -0.16 | - |
Interest Expenses | 700.0% | 8,000 | 1,000 | - | - | - |
Net Income | -2.9% | -76,613,000 | -74,435,000 | -69,393,000 | -49,623,000 | -30,662,000 |
Net Income Margin | -1.9% | -0.24 | -0.23 | -0.22 | -0.16 | - |
Free Cahsflow | 10.7% | -25,239,000 | -28,258,000 | -20,797,000 | -17,413,333 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -0.3% | 543 | 545 | 541 | 547 | 567 |
Current Assets | -0.1% | 388 | 388 | 404 | 411 | 433 |
Cash Equivalents | 8.4% | 90.00 | 83.00 | 167 | 172 | 348 |
Inventory | 6.3% | 19.00 | 18.00 | 19.00 | 18.00 | 17.00 |
Goodwill | 0.1% | 38.00 | 38.00 | 37.00 | 37.00 | 37.00 |
Liabilities | 3.9% | 112 | 108 | 98.00 | 89.00 | 101 |
Current Liabilities | 8.1% | 76.00 | 70.00 | 78.00 | 67.00 | 77.00 |
Shareholder's Equity | -1.3% | 431 | 437 | 444 | 458 | 466 |
Retained Earnings | -4.3% | -460 | -441 | -424 | -402 | -383 |
Additional Paid-In Capital | 1.3% | 899 | 887 | 875 | 865 | 854 |
Shares Outstanding | 0.0% | 54.00 | 54.00 | 53.00 | 53.00 | 53.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 10.7% | -25.24 | -28.26 | -20.80 | -7.13 | -19.29 |
Share Based Compensation | 6.0% | 47.00 | 44.00 | 43.00 | 40.00 | 36.00 |
Cashflow From Investing | 4.3% | -228 | -238 | -142 | -127 | 48.00 |
Cashflow From Financing | -51.3% | -4.53 | -3.00 | -5.10 | -2.72 | 186 |
Buy Backs | Infinity% | 1.00 | 0.00 | - | - | - |
100%
84.2%
46.9%
Y-axis is the maximum loss one would have experienced if CareDx was unfortunately bought at previous high price.
10.7%
11.3%
-20.9%
FIve years rolling returns for CareDx.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | new | - | 724,022 | 724,022 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -2.99 | -24,000 | 45,000 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | -109,265 | 222,735 | -% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -44.9 | -17,202,000 | 10,071,000 | 0.01% |
2023-02-17 | TRUIST FINANCIAL CORP | sold off | -100 | -200,000 | - | -% |
2023-02-15 | Steward Partners Investment Advisory, LLC | unchanged | - | -3,295 | 5,705 | -% |
2023-02-15 | State of Wyoming | sold off | -100 | -36,000 | - | -% |
2023-02-15 | Financial Gravity Asset Management, Inc. | new | - | 19.00 | 19.00 | -% |
2023-02-15 | ALLIANCEBERNSTEIN L.P. | unchanged | - | -354,029 | 719,971 | -% |
2023-02-15 | LAZARD ASSET MANAGEMENT LLC | reduced | -81.24 | -115,000 | 16,000 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Mar 13, 2023 | gagnon securities llc | 4.7% | 2,522,063 | SC 13G | |
Feb 15, 2023 | arrowmark colorado holdings llc | 7.48% | 4,003,218 | SC 13G | |
Feb 14, 2023 | bellevue asset management (uk) ltd. | 5.9% | 3,168,448 | SC 13G | |
Feb 10, 2023 | ark investment management llc | 11.56% | 6,188,182 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.84% | 5,270,397 | SC 13G/A | |
Feb 08, 2023 | invesco ltd. | 0.2% | 88,421 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 8.2% | 4,373,662 | SC 13G/A | |
Jan 10, 2023 | alger associates inc | 0.9% | 503,686 | SC 13G/A | |
Jan 10, 2023 | state street corp | 10.74% | 5,747,244 | SC 13G/A | |
Feb 14, 2022 | alger associates inc | 6.2% | 3,270,973 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 2.90 -69.98% | 3.97 -58.90% | 7.16 -25.88% | 13.21 36.75% | 25.43 163.25% |
Current Inflation | 2.82 -70.81% | 3.78 -60.87% | 6.56 -32.09% | 11.75 21.64% | 22.18 129.61% |
Very High Inflation | 2.73 -71.74% | 3.55 -63.25% | 5.84 -39.54% | 10.05 4.04% | 18.43 90.79% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 13, 2023 | 8-K | Current Report | |
Mar 13, 2023 | SC 13G | Major Ownership Report | |
Mar 06, 2023 | 4 | Insider Trading | |
Feb 27, 2023 | 10-K | Annual Report | |
Feb 27, 2023 | 8-K | Current Report | |
Feb 27, 2023 | S-8 | Employee Benefits Plan | |
Feb 15, 2023 | SC 13G | Major Ownership Report | |
Feb 14, 2023 | SC 13G | Major Ownership Report | |
Feb 13, 2023 | 4 | Insider Trading | |
Feb 10, 2023 | SC 13G/A | Major Ownership Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-02 | Seeto Reginald | sold | -44,757 | 15.8772 | -2,819 | see remarks |
2023-02-10 | Seeto Reginald | sold | -131,386 | 15.479 | -8,488 | see remarks |
2023-02-09 | Seeto Reginald | sold | -178,928 | 16.1284 | -11,094 | see remarks |
2023-02-08 | Maag Peter | sold | -51,500 | 15.7543 | -3,269 | - |
2023-02-07 | Seeto Reginald | sold | -50,337 | 16.4019 | -3,069 | see remarks |
2023-02-03 | Seeto Reginald | sold (taxes) | -40,622 | 16.54 | -2,456 | see remarks |
2023-02-03 | Johnson Alexander L | sold (taxes) | -13,794 | 16.54 | -834 | chief business officer |
2023-02-02 | Johnson Alexander L | sold (taxes) | -35,730 | 17.61 | -2,029 | chief business officer |
2023-02-02 | Seeto Reginald | sold | -48,346 | 17.1503 | -2,819 | see remarks |
2023-02-02 | Maag Peter | sold | -85,829 | 17.1659 | -5,000 | - |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues [Abstract] | |||
Revenue | $ 321,793 | $ 296,397 | $ 192,194 |
Operating expenses: | |||
Research and development | 90,388 | 76,525 | 48,941 |
Sales and marketing | 96,027 | 77,245 | 53,858 |
General and administrative | 100,397 | 74,964 | 48,806 |
Total operating expenses | 399,024 | 326,123 | 214,722 |
Loss from operations | (77,231) | (29,726) | (22,528) |
Other income (expense): | |||
Interest income, net | 3,762 | 160 | 271 |
Change in estimated fair value of common stock warrant liability | 107 | 106 | (1,495) |
CARES Act Provider Relief Fund | 0 | 0 | 4,813 |
Other expense, net | (2,872) | (2,628) | (811) |
Total other income (expense) | 997 | (2,362) | 2,778 |
Loss before income taxes | (76,234) | (32,088) | (19,750) |
Income tax (expense) benefit | (379) | 1,426 | 1,036 |
Net loss | $ (76,613) | $ (30,662) | $ (18,714) |
Net loss per share (Note 3): | |||
Basic (in dollars per share) | $ (1.44) | $ (0.59) | $ (0.40) |
Diluted (in dollars per share) | $ (1.44) | $ (0.59) | $ (0.40) |
Weighted-average shares used to compute net loss per share: | |||
Basic (in shares) | 53,321,625 | 52,241,076 | 46,481,772 |
Diluted (in shares) | 53,321,625 | 52,241,076 | 46,481,772 |
Testing services revenue | |||
Revenues [Abstract] | |||
Revenue | $ 263,748 | $ 259,285 | $ 163,610 |
Operating expenses: | |||
Cost of testing services, product, patient and digital solutions | 72,286 | 71,251 | 43,932 |
Product revenue | |||
Revenues [Abstract] | |||
Revenue | 29,251 | 26,832 | 19,302 |
Operating expenses: | |||
Cost of testing services, product, patient and digital solutions | 17,639 | 18,930 | 13,847 |
Patient and digital solutions | |||
Revenues [Abstract] | |||
Revenue | 28,794 | 10,280 | 9,282 |
Operating expenses: | |||
Cost of testing services, product, patient and digital solutions | $ 22,287 | $ 7,208 | $ 5,338 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 89,921 | $ 348,485 |
Marketable securities | 203,168 | 0 |
Accounts receivable | 66,312 | 59,761 |
Inventory | 19,232 | 17,186 |
Prepaid and other current assets | 9,216 | 7,928 |
Total current assets | 387,849 | 433,360 |
Property and equipment, net | 35,529 | 22,044 |
Operating leases right-of-use assets | 34,689 | 17,993 |
Intangible assets, net | 43,051 | 50,195 |
Goodwill | 37,523 | 36,983 |
Restricted cash | 522 | 211 |
Other assets | 3,828 | 5,835 |
Total assets | 542,991 | 566,621 |
Current liabilities: | ||
Accounts payable | 9,942 | 13,337 |
Accrued compensation | 16,902 | 26,042 |
Accrued and other liabilities | 49,131 | 37,922 |
Total current liabilities | 75,975 | 77,301 |
Deferred tax liability | 0 | 415 |
Common stock warrant liability | 32 | 139 |
Deferred payments for intangible assets | 2,418 | 5,041 |
Operating lease liability, less current portion | 33,406 | 17,394 |
Other liabilities | 249 | 455 |
Total liabilities | 112,080 | 100,745 |
Commitments and contingencies (Note 9) | ||
Stockholders’ equity: | ||
Preferred stock: $0.001 par value; 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021 | 0 | 0 |
Common stock: $0.001 par value; 100,000,000 shares authorized at December 31, 2022 and 2021; 53,583,301 and 52,923,360 shares issued at December 31, 2022 and 2021, respectively; 53,533,250 and 52,923,360 shares outstanding at December 31, 2022 and 2021, respectively | 52 | 52 |
Additional paid-in capital | 898,806 | 853,683 |
Accumulated other comprehensive loss | (7,503) | (4,670) |
Accumulated deficit | (460,444) | (383,189) |
Total stockholders’ equity | 430,911 | 465,876 |
Total liabilities and stockholders’ equity | $ 542,991 | $ 566,621 |